Review Article

Esophageal Cancer: Should Gender Be Considered as an Influential Factor for Patient Safety in Drug Treatment?

Table 1

Summary of hazard ratio of men and women with esophageal cancer in clinical trials.

Authors/reference #/yearN
(%Men)
N
(%women)
N
(Women/Men)%
PFS
HR (95% CI)
OS
HR (95% CI)
Cox regression analysisDeath ratio
HR (95% CI)

Robb W.B. et al.
/[4]/2015
146/170
=85.9
24/170
=14.1
24/146
=16.4
metastatic recurrence
F/M
Univariable 0.26(0.06-1.09)
Multivariable
0·35 (0·08, 1·47)
-locoregional recurrence
Univariable
F/M
0·68 (0·24, 1·90)
-

Zhao Y, et al.
/[5]/2015
297/346 =85.849/346
=14.2
49/297
=16.5
--Death
M: 0.89(0.75-1.07)
F:0.83(0.57-1.21)

Dutton S.J. et al. /[2]/2014372/449 =82.977/449
=17.1
77/372
=20.7
M 0.82 (0.67–1.01)
F 0.70 (0.44–1.12)
--

Oppedijk V. et al.
/[7]/2014
298/374
=80
76/374
=20
76/298
=25.5
M/F 1.12(0.67-1.87)--

Swisher S.G. et al. [8]/2010141/157
=90
16/157
=10
16/141
=11.3
-M:1.0(0.5-1.7)
F: 1.0
-

Crehange G. et al./[9]/2007412/446
=92.4
34/446
=7.6
34/412
=8.3
M/F1.4(0.8-2.45)--

Burmeister B.H. et al./[10]/2005206/256
=80.5
50/256
=19.5
50/206
24.3
PFS
M 0.93(0.67-1.29)
F 0.42(0.19-0.91)
M/F:1.28(0.86-1.90)
OS M/F 1.36(0.93-1.99)